ATNM
Price:
$1.73
Market Cap:
$53.90M
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple...[Read more]
Industry
Biotechnology
IPO Date
2012-12-27
Stock Exchange
AMEX
Ticker
ATNM
According to Actinium Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -30290888.00. This represents a change of -127.89% compared to the average of 108.61M of the last 4 quarters.
The mean historical Enterprise Value of Actinium Pharmaceuticals, Inc. over the last ten years is 64.30M. The current -30290888.00 Enterprise Value has changed -4811.00% with respect to the historical average. Over the past ten years (40 quarters), ATNM's Enterprise Value was at its highest in in the December 2014 quarter at 189.45M. The Enterprise Value was at its lowest in in the June 2022 quarter at 468.37K.
Average
64.30M
Median
38.96M
Minimum
21.89M
Maximum
154.75M
Discovering the peaks and valleys of Actinium Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 227.09%
Maximum Annual Enterprise Value = 154.75M
Minimum Annual Increase = -77.64%
Minimum Annual Enterprise Value = 21.89M
Year | Enterprise Value | Change |
---|---|---|
2023 | 60.58M | -59.82% |
2022 | 150.78M | 227.09% |
2021 | 46.10M | 44.84% |
2020 | 31.83M | 29.00% |
2019 | 24.67M | -10.70% |
2018 | 27.63M | 2.73% |
2017 | 26.89M | 22.88% |
2016 | 21.89M | -77.64% |
2015 | 97.87M | -36.75% |
2014 | 154.75M | 20.30% |
The current Enterprise Value of Actinium Pharmaceuticals, Inc. (ATNM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
85.82M
5-year avg
62.79M
10-year avg
64.30M
Actinium Pharmaceuticals, Inc.’s Enterprise Value is less than MiNK Therapeutics, Inc. (23.96M), less than Affimed N.V. (50.05M), less than ImmunoGen, Inc. (8.19B), less than Adaptimmune Therapeutics plc (47.80M), less than Sangamo Therapeutics, Inc. (390.68M), less than Rigel Pharmaceuticals, Inc. (273.69M), less than Fortress Biotech, Inc. (59.35M), less than Reviva Pharmaceuticals Holdings, Inc. (30.20M), less than CTI BioPharma Corp. (1.22B), less than Ocuphire Pharma, Inc. (-9671816.00), less than Annovis Bio, Inc. (113.36M), less than Cassava Sciences, Inc. (1.04B), less than Axsome Therapeutics, Inc. (4.12B), less than Seres Therapeutics, Inc. (282.37M), less than Reviva Pharmaceuticals Holdings, Inc. (30.20M), less than Eyenovia, Inc. (57.40M), less than Cognition Therapeutics, Inc. (-9122761.00), less than TransCode Therapeutics, Inc. (5.63M), less than Kodiak Sciences Inc. (162.26M), less than Exelixis, Inc. (9.81B), less than TG Therapeutics, Inc. (3.89B), less than Viking Therapeutics, Inc. (7.57B), less than Madrigal Pharmaceuticals, Inc. (7.02B), less than BioXcel Therapeutics, Inc. (73.13M),
Company | Enterprise Value | Market cap |
---|---|---|
23.96M | $28.86M | |
50.05M | $50.40M | |
8.19B | $8.73B | |
47.80M | $212.26M | |
390.68M | $389.37M | |
273.69M | $249.41M | |
59.35M | $47.13M | |
30.20M | $34.95M | |
1.22B | $1.20B | |
-9671816.00 | $31.74M | |
113.36M | $117.36M | |
1.04B | $1.24B | |
4.12B | $4.24B | |
282.37M | $140.98M | |
30.20M | $36.43M | |
57.40M | $44.01M | |
-9122761.00 | $18.79M | |
5.63M | $8.76M | |
162.26M | $205.72M | |
9.81B | $9.87B | |
3.89B | $3.86B | |
7.57B | $7.62B | |
7.02B | $7.25B | |
73.13M | $25.78M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Actinium Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Actinium Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Actinium Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the 3-year average Enterprise Value for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the 5-year average Enterprise Value for Actinium Pharmaceuticals, Inc. (ATNM)?
How does the current Enterprise Value for Actinium Pharmaceuticals, Inc. (ATNM) compare to its historical average?